UPDATED Dec 08, 2023
Discover large cap U.S. Pharmaceuticals & Biotech companies that are on the NYSE and NASDAQ. These Pharmaceuticals & Biotech Companies are organised by Market Cap.
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| LLYEli Lilly | US$598.05 | 2.4% | 65.7% | US$529.0b | US$619.14 | PE107.8x | E34.1% | 0.8% | ||
| JNJJohnson & Johnson | US$154.42 | -2.5% | -12.1% | US$374.1b | US$174.91 | PE26.6x | E11.0% | 3.1% | ||
| MRKMerck | US$103.75 | 0.3% | -4.6% | US$263.2b | US$123.61 | PE57.1x | E35.6% | 2.8% | ||
| ABBVAbbVie | US$149.28 | 4.1% | -8.5% | US$261.2b | US$167.53 | PE40.7x | E17.3% | 4.2% | ||
| TMOThermo Fisher Scientific | US$489.77 | -1.3% | -12.6% | US$190.9b | US$532.09 | PE31.9x | E11.9% | 0.3% | ||
| DHRDanaher | US$217.49 | -2.7% | -19.3% | US$161.8b | US$240.74 | PE27.4x | E4.2% | 0.5% | ||
| PFEPfizer | US$28.78 | -0.4% | -44.4% | US$161.7b | US$40.41 | PE15.5x | E18.9% | 5.7% | ||
| AMGNAmgen | US$269.12 | -1.2% | -3.4% | US$145.2b | US$276.06 | PE19x | E5.7% | 3.2% | ||
| BMYBristol-Myers Squibb | US$50.31 | 0.4% | -36.2% | US$102.1b | US$64.13 | PE12.4x | E11.4% | 4.5% | ||
| GILDGilead Sciences | US$79.02 | 1.8% | -10.2% | US$97.3b | US$90.39 | PE16.8x | E7.2% | 3.8% | ||
| VRTXVertex Pharmaceuticals | US$350.15 | -0.3% | 12.1% | US$91.2b | US$396.25 | PE26x | E10.4% | n/a | ||
| REGNRegeneron Pharmaceuticals | US$840.14 | 3.1% | 12.0% | US$90.3b | US$912.57 | PE22.4x | E9.2% | n/a | ||
| ZTSZoetis | US$184.60 | 3.1% | 20.3% | US$83.5b | US$212.39 | PE37.2x | E8.7% | 0.8% | ||
| SGENSeagen | US$218.98 | 2.9% | 76.6% | US$41.2b | US$228.91 | PS18x | E72.0% | n/a | ||
| IQVIQVIA Holdings | US$215.28 | -0.8% | 3.2% | US$39.2b | US$230.52 | PE35.2x | E16.1% | 0% | ||
| AAgilent Technologies | US$127.20 | -1.2% | -16.8% | US$37.6b | US$133.41 | PE30x | E10.9% | 0.7% | ||
| BIIBBiogen | US$239.29 | 2.0% | -16.1% | US$34.6b | US$315.50 | PE23.7x | E16.8% | n/a | ||
| MRNAModerna | US$80.32 | 0.6% | -54.7% | US$30.5b | US$136.81 | PS3.4x | E57.5% | n/a | ||
| HZNPHorizon Therapeutics | US$116.30 | 0.06% | 82.8% | US$26.6b | US$116.50 | PE60.8x | E16.4% | n/a | ||
| WSTWest Pharmaceutical Services | US$342.24 | -2.7% | 43.2% | US$25.2b | US$372.19 | PE45.3x | E11.2% | 0.2% | ||
| BNTXBioNTech | US$103.43 | 4.1% | -39.3% | US$24.2b | US$133.84 | PE8.3x | E-46.8% | n/a | ||
| MTDMettler-Toledo International | US$1,090.52 | -1.3% | -25.1% | US$23.9b | US$1,115.67 | PE27.2x | E5.2% | n/a | ||
| ALNYAlnylam Pharmaceuticals | US$170.04 | -0.8% | -26.5% | US$22.2b | US$222.11 | PS12.4x | E61.4% | n/a | ||
| ICLRICON | US$272.46 | 1.2% | 39.9% | US$22.1b | US$286.21 | PE43.7x | E18.5% | n/a |